Acadia Pharmaceuticals (ACAD) PT Raised to $37 at Deutsche Bank
Deutsche Bank analyst David Hoang raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $37.00 (from $32.00) while maintaining a Buy rating.
Deutsche Bank analyst David Hoang raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $37.00 (from $32.00) while maintaining a Buy rating.